---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic burden and healthcare resource utilization"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic burden and healthcare resource utilization. Topics: Health care resource utilization and costs per patient per month by line of therapy in 3203 premenopausal women with HR+/HER2- metastatic breast cancer, US commercial claims; All-cause costs per patient per month and treatment patterns by line in 5563 privately insured participants with HR+/HER2- metastatic breast cancer before CDK4/6 inhibitors; Anticancer and supportive care drug costs by subtype in 15 215 participants in a US nationwide database, 2011 to 2021; Resource utilization and costs in the year after first-line CDK4/6 inhibitor initiation in 901 Medicare-enrolled participants; 9 further topics. 13 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/economic-burden-and-healthcare-resource-utilization"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic burden and healthcare resource utilization

<a id="heading-2.2.1.8.2"></a>

## 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

### Health care resource utilization and costs per patient per month by line of therapy in 3203 premenopausal women with HR+/HER2- metastatic breast cancer, US commercial claims

> “A total of 3203 patients received first-line, 2194 received second-line, and 1242 received third-line therapy for mBC. Mean number of IP days PPP6 M were 1.6, 1.3, and 1.5 days in the first, second, and third lines, respectively. Mean number of days with OP services PPP6 M was 31.4, 30.9, and 23.3 in the first, second, and third lines, respectively.”
> “Among patients receiving ET, mean total healthcare costs were $6521, $4440, and $4555 PPPM in the first, second, and third line, respectively. Among patients receiving chemotherapy, mean total healthcare costs were $16,842, $12,868, and $16,129 PPPM in the first, second, and third line, respectively.”

Source: [Gauthier et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29556908/)

<a id="topic-2.2.1.8.2-2"></a>

### All-cause costs per patient per month and treatment patterns by line in 5563 privately insured participants with HR+/HER2- metastatic breast cancer before CDK4/6 inhibitors

> “Among 5,563 eligible patients, endocrine therapy was the most common first-line (1L) therapy; its utilization trended downward from 63% (1L) to 23% (4L), with a simultaneous increase in chemotherapy use, 25% (1L) to 50% (4L).”
> “The average per patient monthly all-cause costs were $14,424. The 12-month indirect costs for short-term disability were substantially higher in MBC patients ($10,397) than in matched noncancer patients ($394).”

Source: [Goyal et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32755262/)

<a id="topic-2.2.1.8.2-3"></a>

### Anticancer and supportive care drug costs by subtype in 15 215 participants in a US nationwide database, 2011 to 2021

> “The mean total per-patient treatment and supportive care drug cost using publicly available Medicare prices was $334 812 for patients with HR-positive and ERBB2-positive MBC, $284 609 for patients with HR-negative and ERBB2-positive MBC, $104 774 for patients with HR-positive and ERBB2-negative MBC, and $54 355 for patients with TNBC.”
> “From 2011 to 2019 (most recent complete year 1 data are for patients diagnosed in 2019), annual costs in year 1 increased from $12 986 to $80 563 for ERBB2-negative and HR-positive MBC, $99 997 to $156 712 for ERBB2-positive and HR-positive MBC, and $31 397 to $53 775 for TNBC.”
> “Second, our study focused on outpatient treatment and did not account for other medical costs, such as surgery, radiation, imaging, and hospital stays.”

Source: [Jaber Chehayeb et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9709649/)

<a id="topic-2.2.1.8.2-4"></a>

### Resource utilization and costs in the year after first-line CDK4/6 inhibitor initiation in 901 Medicare-enrolled participants

> “901 patients met the inclusion criteria with a mean age of 74 years (SD = 6.84). Nearly 24% (n = 214) had an IP admission in the 6 months following CDK4/6i initiation.”
> “Roughly 30% (n = 271) of patients had an ED visit, with a mean of 2.1 (SD = 1.54) visits per patient among those who had a visit.”
> “Mean total health care costs over the 1-year period following CDK4/6is were $62,228 (95% CI = 52,281-73,029) per patient with the main drivers being OP services ($31,686 [95% CI = 27,168-36,925]) and pharmacy costs ($22,727 [95% CI = 19,273-25,931]).”

Source: [Behan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11695835/)

<a id="topic-2.2.1.8.2-5"></a>

### Projected lifetime health care costs after first-line CDK4/6 inhibitor plus aromatase inhibitor in a US Medicare-eligible population

> “Total lifetime health care costs were also similar ($865,000 [95% CR = $807,400-$925,000], $866,800 [95% CR = $786,000-$965,000], and $901,000 [95% CR = $809,000-$1,004,600], respectively).”
> “All-cause medical costs and CDK4/6i drug costs were based on an analysis of patients aged 65 years and older in Optum Clinformatics DataMart.”

Source: [Sun et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12467758/)

<a id="topic-2.2.1.8.2-6"></a>

### Cost of disease progression in 5709 participants with metastatic breast cancer, US commercial and Medicare Advantage claims

> “Of 5,709 patients with mBC, 3,707 patients with mCRC, and 5,201 patients with mLC, 56.8% of patients with mBC, 58.1% of those with mCRC, and 80.3% of those with mLC patients had evidence of disease progression over 12 months.”
> “Per‐patient‐per‐month costs, which accounted for variable follow‐up time, were almost twice as high among progressors versus nonprogressors in patients with mBC, mCRC, and mLC. In each of the three cancer types, delays in progression were associated with lower health care costs.”

Source: [Reyes et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6738320/)

<a id="topic-2.2.1.8.2-7"></a>

### End-of-life costs and resource utilization in the last 6 months, 3878 participants in US commercial claims

> “Of the 3,878 females included, 18.5% (n = 718) met the criteria for EOL.”
> “In adjusted analyses, the EOL cohort had 4.15 times higher 6-month total healthcare costs (EOL, $72,112 vs NEOL, $17,137; p < 0.001). NEOL month-to-month mean total healthcare costs fluctuated between $2336-$3145, while EOL costs increased steadily from $8,956 in the sixth month prior to death to $19,326 in the last month of life.”
> “EOL month-to-month costs increased precipitously in the last 2 months of life and were driven by acute inpatient care.”

Source: [Bramley et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/27248201/)

<a id="topic-2.2.1.8.2-8"></a>

### Cancer-attributable medical costs by phase of care and stage at diagnosis, SEER-Medicare

> “Annualized average cancer-attributable costs for medical care (Medicare Parts A and B) and oral prescription drugs (Medicare Part D) were estimated by subtracting costs between cancer patients and matched controls. Costs are reported in 2019 US dollars.”
> “Overall annualized average costs were highest in the EOL-cancer death phase, followed by the initial and continuing phases”

Source: [Mariotto et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9514601/)

| Breast cancer, stage at diagnosis | Initial phase | Continuing phase | End-of-life phase, cancer death |
| --- | --- | --- | --- |
| Distant, medical services (thousand 2019 US dollars) | “$67.4” | “$22.3” | “$91.9” |
| All stages, medical services (thousand 2019 US dollars) | “$33.7” | “$3.5” | “$73.2” |

Source: [Mariotto et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9514601/)

<a id="topic-2.2.1.8.2-9"></a>

### Projected US prevalence and total medical and productivity costs of metastatic breast cancer, 2015 to 2030

> “In 2030, we estimated there would be 246 194 prevalent cases of mBC, an increase of 54.8% from the 2015 estimate of 158 997. We estimated total costs (medical and productivity) of mBC across all age groups and phases of care were $63.4 billion (95% sensitivity range = $59.4-$67.4 billion) in 2015 and would increase to $152.4 billion (95% sensitivity range = $111.6-$220.4 billion) in 2030, an increase of 140%.”

Source: [Gogate et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8364673/)

<a id="topic-2.2.1.8.2-10"></a>

### Health care contact days in the year after diagnosis among Medicare beneficiaries with metastatic breast cancer

> “In the year after diagnosis, beneficiaries with colorectal cancer had the highest mean (SD) contact days (62.9 [48.1]), followed by those with lung (60.2 [47.0]), breast (48.7 [47.9]), and prostate (40.1 [42.4]) cancers.”
> “Across all cancer types, mean contact days increased from 2008 to 2019 with a prominent increase in ambulatory days from 2016 onward; the largest increase in contact days was observed for breast cancer (44.9 [95% CI, 38.7-52.2] to 57.6 [95% CI, 46.9-70.8]).”

Source: [Gupta et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690425/)

<a id="topic-2.2.1.8.2-11"></a>

### Encounter days in the first year of treatment among 2949 SEER-Medicare participants aged 67 years or older

> “We assessed time toxicity using the number of encounter days patients interacted with the healthcare system per 100 days, within the first year of starting cancer treatment.”
> “Patients with more than three comorbidities had significantly higher encounter days compared to those without comorbidities [RR 1.36 (95% CI 1.26, 1.46)]. Receipt of radiotherapy [RR: 1.45 95% CI (1.37, 1.54)] was associated with more encounter days compared to not receiving radiotherapy”

Source: [Atre et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38816556/)

<a id="topic-2.2.1.8.2-12"></a>

### Systematic review of direct and indirect costs of breast cancer by stage

> “Across cost categories, cost ranges tended to be higher in the US than any other country. Metastatic breast cancer was associated with higher costs than earlier-stage cancer. When indirect costs were accounted for, particularly in terms of productivity loss, they tended to be higher than any other estimated direct cost (e.g., diagnosis, drug, and other medical costs).”

Source: [Franklin et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11213812/)

<a id="topic-2.2.1.8.2-13"></a>

### Phase-specific costs per patient per month after first-line CDK4/6 inhibitor in 5435 participants, Japanese nationwide claims

> “Among 5435 patients (median age 72.3 years), active treatment phases showed drug-dominated cost structures: first-line per-patient per-month (PPPM) cost was 482,936 Japanese yen (JPY) (drug 85%–90%), second-line 361,615 JPY (81%), and extended chemotherapy 255,922 JPY (66%). A marked inversion occurred in the palliative phase (PPPM 233,824 JPY; drug 11%, inpatient 70%) and terminal phase (PPPM 412,149 JPY; drug 17%, inpatient 69%).”
> “Death-anchored analysis of 1111 decedents identified a transition 2 months before death, when inpatient costs first exceeded drug costs.”

Source: [Kashiwa et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13723614/)

Additional sources: [Goyal et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31060392/); [Allen (2010)](https://pubmed.ncbi.nlm.nih.gov/20873957/); [Sorensen et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22617734/)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
